SCHEMBL19099546

SCHEMBL19099546

CC(CS)OCc1ccccc1Cl

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 3/20 0.48
▸ SLC6A2 P23975 1/20 0.43
▸ SLC6A4 P31645 1/20 0.43
▸ SLC6A3 Q01959 1/20 0.43
▸ MAOB P27338 2/20 0.43
▸ MAOA P21397 1/20 0.43
▸ NR4A2 P43354 1/20 0.41
▸ PNMT P11086 1/20 0.39
▸ MAPT P10636 3/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ LMNA P02545 1/20 0.38
▸ TAAR1 Q96RJ0 3/20 0.38
▸ NPC1 O15118 2/20 0.38
▸ CASP3 P42574 1/20 0.37
▸ SENP8 Q96LD8 1/20 0.37
▸ SENP7 Q9BQF6 1/20 0.37
▸ SENP6 Q9GZR1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18722577 0.84 IDO1 (0.50) IDO1SLC6A2SLC6A4SLC6A3MAOB
SCHEMBL18596801 0.81 IDO1 (0.52) IDO1SLC6A2SLC6A4SLC6A3MAOB
SCHEMBL10314843 0.81 IDO1 (0.55) IDO1SLC6A2SLC6A4SLC6A3MAOB
SCHEMBL21466573 0.81 IDO1 (0.47) IDO1SLC6A2SLC6A4SLC6A3MAOB
SCHEMBL19098941 0.80 SMN1; SMN2 (0.40) IDO1SLC6A2SLC6A4SLC6A3MAPT
SCHEMBL15061213 0.78 IDO1 (0.44) IDO1SLC6A2SLC6A4SLC6A3MAOB
SCHEMBL10775814 0.74 IDO1 (0.47) IDO1SLC6A2SLC6A4SLC6A3MAOB
SCHEMBL19099544 0.73 TAAR1 (0.45) LMNATAAR1
SCHEMBL11763588 0.73 TSHR (0.44) IDO1MAPT
SCHEMBL11778626 0.73 IDO1 (0.50) IDO1SLC6A2SLC6A4SLC6A3MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10189777-B2 Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease LYCERA CORPORATION (US) 2019-01-29 — — US disclosed
US-20170190659-A1 BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE WILMINGTON TRUST, NATIONAL ASSOCIATION 2017-07-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10189777-B2 Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease RORC, RORB, RORA IDO1 867/4885SLC6A2 4787/4885SLC6A4 4556/4885
US-20170190659-A1 BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE RORB, RORA, RORC IDO1 657/4885SLC6A2 4767/4885SLC6A4 4648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback